KMART
Chain to Close More Locations
Kmart is closing an additional 64 locations, according to a
person familiar with the matter, as the struggling department-store
chain continues to shrink its footprint.
The latest closures, which were announced to employees, are in
addition to a decision in April by parent Sears Holdings Corp. to
close about 68 Kmart stores this year. The chain had 941 locations
as of Jan. 30, meaning it has now announced plans to close about
14% of its locations.
A Sears spokesman said the company will provide an updated store
count when it releases its next quarterly earnings report. News of
the closures was earlier reported by Business Insider.
The 64 Kmart store closings include 17 locations that are part
of Seritage Growth Properties, a real-estate investment trust that
Sears created last year, the person familiar with the situation
said. Seritage disclosed the 17 closures in a securities filing on
Friday, but didn't say whether they were Sears or Kmart
locations.
Over the past five years, Sears Holdings has shut more than 400
Kmart discount stores and supercenters, or about a third of the
chain's locations, according to regulatory filings. In an unusual
move, the retailer recently spent money to remodel and reopen a
location in a Chicago suburb.
Kmart posted an operating loss of $292 million on sales of $10.2
billion in its last fiscal year, ended in February. It has
cumulative operating losses of $1.06 billion in the last three
years. Sears Holdings ended the latest quarter with about $276
million in cash and long term debt of $3.4 billion.
Last week, Moody's downgraded its rating on Sears' speculative
grade liquidity rating noting the company will continue to rely on
external financing and selling assets to fund its operating losses.
Moody's estimated the company's operating cash flow will be
negative $1.5 billion this year.
--Suzanne Kapner
SANOFI
Drugmaker Sues Merck Over Patents
PARIS -- Sanofi SA said it filed a lawsuit against Merck &
Co. for alleged patent infringements to prevent the U.S. drugmaker
from launching a rival version of the French pharmaceutical giant's
best-selling diabetes treatment Lantus.
In the filing in the U.S. District Court of Delaware, Sanofi
said Monday it claims that Merck Sharp & Dohme Corp., Merck
& Co.'s international division, violated as many as 10 patents
held by the French company, including ones for its insulin Lantus
and its insulin-delivery device soloSTAR.
The Paris-based drug company said it started the legal
proceedings against Merck after the U.S. company's filing for
new-drug applications with the U.S. Food & Drug
Administration.
A spokeswoman for Merck said the company's product "doesn't
infringe Sanofi's patents."
Sanofi shares traded at EUR69.63 ($77.68), up 62 European cents,
at Monday's close.
The French drugmaker's all-important diabetes business is under
siege, as a flurry of pharmaceutical companies seek to sell
knockoffs of its blockbuster insulin Lantus in the U.S. The
expected launch of lower-cost copies of Lantus, as well as pricing
pressure on diabetes drugs in the U.S., is rapidly eroding earnings
at Sanofi's diabetes division, which accounts for about 20% of the
company's total revenue.
In the first six months of the year, diabetes revenue fell 6% to
EUR2.9 billion, hit by a 15% drop in Lantus sales to EUR2.38
billion.
The company has said it expects revenue from diabetes drugs to
continue to decline as competition among insulin makers
intensifies.
In January 2014, Sanofi filed a suit against Eli Lilly & Co.
to defend its patents on Lantus.
It reached a deal with the U.S. drugmaker nearly two years
later, under which Lilly agreed to delay the launch of its insulin
to December 2016 and pay royalties to Sanofi.
In a bid to replenish its new drugs pipeline and revive growth,
Sanofi for months had pursued U.S. biotech Medivation Inc.
Medivation, a Nasdaq-listed company, focuses on hard-to-treat
cancers, markets the prostate-cancer therapy Xtandi, and has two
other oncology assets in clinical development.
U.S. pharmaceutical company Pfizer Inc. beat out Sanofi,
acquiring Medivation for $14 billion in August.
--Noemie Bisserbe and Inti Landauro
NJOY
E-Cigarette Company Seeks Chapter 11
E-cigarette manufacturer NJOY Inc. filed for bankruptcy
protection Friday after struggles with a new product coupled with
litigation and regulatory expenses took a toll on the company's
bottom line.
The chapter 11 filing in the U.S. Bankruptcy Court in
Wilmington, Del., is designed to spur interest in NJOY as the
Scottsdale, Ariz., company looks to sell its business and deal with
debts exceeding $32 million.
NJOY said it began exploring a sale earlier this year but didn't
receive any offers. A second attempt at finding a buyer in June
sparked some interest, and court papers indicate the company plans
to sell itself through an auction process overseen by the
court.
NJOY products include disposable e-cigarettes, rechargeable
e-cigarettes, vaping systems and e-liquids, court papers say. NJOY
products can be found in drugstores, convenience stores and
online.
In late 2013, NJOY launched a new e-cigarette product called
Kings 2.0, which failed to gain traction and contributed to a $15.2
million decline in gross profit during the six months after the
company shelved the product. Overall sales at NJOY plummeted to
$7.4 million in 2015 from a peak of $92.9 million in 2013.
Court papers say NJOY also "incurred substantial expenses" in
addressing new Food and Drug Administration regulations aimed at
e-cigarettes and related products. On top of that, the e-cigarette
manufacturer incurred litigation fees tied to a patent-infringement
lawsuit.
The company has lined up $6 million in bankruptcy financing from
existing lenders, court filings say.
As the market for e-cigarettes grew, NJOY attracted the
attention of venture capitalists. According to WSJ Pro Venture
Capital, it has received funding from Napster co-founder Sean
Parker, Homewood Capital, Catterton Partners and a venture fund
started by PayPal co-founder Peter Thiel.
The law firm Gellert Scali Busenkell & Brown LLC is handling
the chapter 11 case, SierraConstellation Partners LLC is financial
adviser and CohnReznick Caiptal Markets Securities is investment
banker.
The case, numbered 16-12076, has been assigned to Judge
Christopher S. Sontchi.
--Sarah Chaney
TERRAFORM
Sister Firms Weigh Selling Themselves
TerraForm Global Inc. and TerraForm Power Inc. said Monday they
are considering selling themselves, as the sister companies face
trouble due to the bankruptcy of parent company SunEdison Inc.
The two companies own major wind and solar power projects
developed by SunEdison, which filed for chapter 11 bankruptcy
protection in April. SunEdison launched the sister companies into
the public stock market in 2014 and 2015, respectively, and is
considering selling its controlling stakes in the sister
companies.
The TerraForm companies were a central element of the financial
engineering that fueled SunEdison's fast growth.
But SunEdison's market capitalization plummeted in 2015 and 2016
as investors and business partners lost confidence amid mounting
debt, incomplete deals and doubts about the company'sfinances.
TerraForm Global and TerraForm Power said they were open to
finding a new sponsor to replace SunEdison but were also preparing
to operate as independent companies. SunEdison performed some
management functions for the TerraForm companies, including their
accounting practices, and its bankruptcy caused the companies to
delay their financial filings.
The TerraForm companies said they were working with SunEdison
toward a potential deal but that decisions made by the parent may
require bankruptcy court approval.
TerraForm Global shares rose 1.5% in premarket trading;
TerraForm Power shares were inactive.
--Austen Hufford
(END) Dow Jones Newswires
September 20, 2016 02:48 ET (06:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024